

- **Full Name:** Ecaterina E. Dumbrava, MD
 - **Current Position & Affiliation:** Assistant Professor, The Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
 - **Country:** United States
-

• **Educational Background:**

- University of Medicine and Pharmacy "Iuliu-Hatieganu", Cluj-Napoca, Romania, MD, 2008, General Medicine
- Paris South University, Orsay, France, MSc, 2015, Master of Science Health Biology-Oncology/ Early Drug Development
- Clinical Residency, Internal Medicine/Medical Oncology, Third Medical Hospital, Cluj-Napoca, Romania, 1/2009-4/2009
- Clinical Residency, Medical Oncology/Internal Medicine, Assistance Publique Hôpitaux de Marseille, Marseille, France, 5/2009-5/2011
- Clinical Fellowship, Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France, 5/2011-10/2013
- Research Fellowship, Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France, Professor JC. Soria, MD, PhD, 11/2013-10/2014
- Postdoctoral Fellow, Translational Molecular Pathology Department, The University of Texas, MD Anderson Cancer Center, Houston, TX, Professor I. Wistuba, MD, 1/2015-12/2015
- Fellow, Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 7/2016-6/2017
- Chief Fellow, Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 7/2017-6/2018
- Fellowship, NIH/NCI Cancer Therapy Evaluation Program (CTEP), Houston, 2/2018-3/2018

• **Professional Experience:**

Dr Dumbrava is a Medical Oncologist and an Assistant Professor in the Department of Investigational

Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, Houston, Texas. She completed her medical oncology training at Gustave Roussy Cancer Center in Villejuif, France, followed by a Master of Science Degree from Paris-South University and a postdoctoral fellowship in the Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. She completed two years of Clinical Fellowship in the Investigational Cancer Therapeutics Department, where she was elected Chief Fellow and during which she did a clinical research rotation at National Cancer Institute (NCI)/Cancer Therapy Evaluation Program (CTEP). She

joined the Department of Investigational Cancer Therapeutics in August 2018 as an Assistant Professor. She is also member of the Andrew M. McDougall Brain Metastasis Clinic. Dr Dumbrava was the FY19 K12 Paul Calabresi Scholar Award and FY21 Gateway Foundation for Cancer Research

Award recipient. Dr Dumbrava is leading the HER2 Working Group in the Investigational Cancer Therapeutics Department at The University of Texas MD Anderson Cancer Center and she also an active member in the Immunotherapy and Cellular Therapies Working Group. Her main area of research lies in targeting p53 and HER2 and developing cellular therapies for solid tumors and genomically matched combination therapies and personalized immunotherapy clinical trials

• **Professional Organizations:**

- American Society of Clinical Oncology – ASCO- Member, 2012-present
- European Society of Medical Oncology – ESMO- Member, 2012-present
- American Association for Cancer Research – AACR- Member, 2014-present
- Society for Immunotherapy of Cancer- SITC- Member, 2019-present
- Associate Scientific Member Institutional Board Review, The University of Texas MD Anderson Cancer Center, Houston, TX- Member, 2019-present
- CARTOX committee; The University of Texas MD Anderson Cancer Center, Houston, TX, Member, 2018-present

• **Main Scientific Publications:**

1. Jovelet C*, **Ileana E***, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. *Clin Cancer Res* 22(12):2960-8, 6/2016. e-Pub 1/2016. PMID: 26758560.
2. **Ileana-Dumbrava E**, Subbiah V. Autoimmune hypophysitis. *Lancet Oncol* 19(2):e123, 2/2018. PMID: 29413466.
3. **Dumbrava EEI**, Meric-Bernstam F. Personalized cancer therapy- leveraging a knowledge base for clinical decision-making. *Cold Spring Harb Mol Case Study* 4(2):1-9, 4/2018. PMCID: PMC65880252.
4. Kurnit K, **Dumbrava EI**, Litzenburger B, Khotskaya Y, Johnson A, Yap T, Rodon J, Zeng J, Shufean A, Bailey A, Sánchez N, Holla V, Mendelsohn J, Shaw K; Bernstam E, Mills G, Meric Bernstam F. Precision oncology decision support: current approaches and strategies for the future. *Clinical Cancer Research* 24(12):2719-2731, 6/2018. PMCID: PMC66004235.
5. **Ileana Dumbrava E**, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. *Expert Opin Drug Discov* 13(8):685-690, 8/2018. e-Pub 5/2018. PMID: 29792354.
6. **Dumbrava EI**, Ivan D, Subbiah V. Hypopigmented Skin Lesions After Immunotherapy. *JAMA Oncol* 4(8):1118-1119, 8/2018. PMCID: PMC6529200.
7. **Ileana Dumbrava E**, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy. *J Immunother* 41(7):336-339,

9/2018. PMID: PMC6086752.

8. **Ileana Dumbrava E**, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw K, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. *JCO Precision Oncology*, 10/2019. PMID: PMC67446516.
9. **Dumbrava EI**, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant Mutations. *JCO Precis Oncol* 3, 2019. e-Pub 4/2019. PMID: PMC6741435.
10. Subbiah V*, **Dumbrava EI***, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul S, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. *Exp Hematol Oncol* 9:7, 2020. e-Pub 4/2020. PMID: PMC7171918.
11. Marcelo-Lewis KL, Moorthy S, **Ileana-Dumbrava E**. Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors. *J Immunother Precis Oncol*. 2020 Aug 5;3(3):121-127. PMID: 35663256; PMID: PMC9165574.
12. **Dumbrava EE**, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. *ESMO Open* 6(5):100230, 10/2021. e-Pub 8/2021. PMID: PMC8414046.
13. Greenbaum U, **Dumbrava EI**, Biter AB, Haymaker CL, Hong DS. Engineered T-cell Receptor T Cells for Cancer Immunotherapy. *Cancer Immunol Res* 9(11):1252-1261, 11/2021. PMID: 34728535.
14. Yap TA, Hamilton E, Bauer T, **Dumbrava EE**, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. *JCO Precis Oncol*. 2022 Feb;6:e2100456. doi: 10.1200/PO.21.00456. PMID: 35138920; PMID: PMC8865521.
15. Piha-Paul SA, **Dumbrava EI**, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. *Onco Targets Ther* 14:3037-3049,

2021. e-Pub 5/2021. PMID: PMC8114359.

16. Barber FD, Campbell E, Yamamura Y, Patterson CJ, Hartnett AC, Kinahan H, Miller VA, Brink AL, Poullard A, Urschel GE, Brantley A, Cepeda IG, Goswami P, Charles S, Philip S, Bresser S, Musekiwa-Adjei S, Perez N, Le H, Phillips P, Subbiah V, Meric-Bernstam F, **Dumbrava EE**. Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience. *J Adv Pract Oncol*. 2022 Sep;13(7):664-672. Epub 2022 Oct 12. PMID: 36199491; PMID: PMC9514129.
17. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, **Dumbrava EE**. Phase Ib study of eprentapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. *ESMO Open*. 2022 Oct;7(5): Epub 2022 Sep 7. PMID: 36084396; PMID: PMC9588880.